Balram Bhargava - Latest News Update, Information, Photos & Videos on Balram Bhargava at Lokmat Times

Dr Balram Bhargava, Director-General (DG) of the Indian Council of Medical Research (ICMR) on Monday said that the ongoing second wave of the novel coronavirus in India is 'less severe' than the previous one.Speaking to , Dr Bhargava said: "Very clearly, we find that the symptoms are much less. As I mentioned that the symptoms of joint ache, fatigue, muscle ache, loss of smell or sore throat are much less compared to the first wave. However, shortness of breath is higher in this wave."He further said that only a marginally high proportion of COVID-19 patients are of younger age and that the average of patients in the first wave was 50 years and in this wave, it is 49 years. He also said that the older population continues to be more vulnerable to be admitted in the hospital in the current wave."From zero to 19 years - the difference was 5.8 per cent versus 4.2 per cent, and in 20-40 years, the difference was 25 per cent versus 23 per cent. There is a marginal difference in this. More than 70 per cent were above or equal to 40 years of age. A higher number of asymptomatic individuals got admitted this year, than a higher proportion of patients admitted with breathlessness," he said."There is no change in the death rate between the first wave and the second wave. Similar trends are being seen across all the states because this is a countrywide data of a national registry data which has been collected of only hospitalised patients, so this is 10,000 hospitalised patients that are being analysed," added Dr Bhargava.The ICMR chief further opined that there was a tremendous amount of laxity regarding the pandemic and many instances of COVID-inappropriate behaviour was also seen. He also stressed that the RT-PCR test measures two or more genes in the body and there is no chance of missing the detection of a COVID-19 mutant through the test."I would like to emphasise that the RT-PCR test that we are utilising, they measure two or more genes and they never miss a test... We have always used two or more genes for testing and therefore missing is absolutely impossible... It can find any kind of mutant because it measures two or more genes at different sites," he told .Dr Bhargava further said that the rate of transmissibility of the 'double mutant' found in India has not yet been established.Three main variants from the United Kingdom, South Africa and Brazil have already been found in India.As the second wave of the coronavirus intensifies, India yet again reported the highest single-day spike of COVID-19 cases with over 2.73 lakh fresh infections and 1,619 deaths in the last 24 hours.With this, the total number of positive cases in the country to 1,50,61,919. There are currently 19,29,329 active cases in the country as of Monday. The death toll reached 1,78,769 as of Monday.( With inputs from ANI )Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Balram BhargavaFOLLOW

Balram bhargava, Latest News

A man in Uttar Pradesh's Lucknow has filed a complaint against Serum Institute of India (SII) CEO Adar Poonawala and Dr. Balram Bhargava, head of the Indian Council of Medical Research (ICMR) after he alleged that no antibodies were formed in his bod ...

A man from Lucknow has filed a police complaint against Serum Institute of India CEO Adar Poonawalla, ICMR director-general Dr Balram Bhargava and others on Tuesday alleging that no antibodies against COVID-19 were developed in his body despite being ...

At-home COVID-19 tests should be available in the market in the next three to four days, the Indian Council of Medical Research (ICMR) said on Thursday. ...

With 4,205 COVID-related deaths in the last 24 hours, India reported another grim record of the highest single-day death ... ...

The Ministry of health on Tuesday informed that over 1 lakh active Covid-19 cases are in 13 states and less than 50,000 Covid-19 active cases are in 17 states across the country. ...

The Centre on Wednesday reviewed the preparedness of five States in eastern India to face the current phase of the COVID pandemic and highlighted five critical areas of action. ...

Covaxin, India's indigenous vaccine against COVID-19 demonstrated "overall interim clinical efficacy" of 78 per cent and 100 per cent efficacy against "severe COVID-19 disease" in Phase-III trials, informed Bharat Biotech and Indian Council of Medica ...

Dr Balram Bhargava, Director-General (DG) of the Indian Council of Medical Research (ICMR) on Monday said that the ongoing second wave of the novel coronavirus in India is 'less severe' than the previous one. ...